November 11, 2024 at 8:23 am

indie Semiconductor Defies Industry Headwinds with Strong Q3 Performance and Strategic ADAS Wins, Sets Sights on Accelerated Growth

indie Semiconductor (NASDAQ: INDI) reported Q3 2024 revenue of $54 million, reflecting a 3.1% sequential increase but an 11% decline compared to the same period in 2023. Despite a challenging automotive market, the company met revenue expectations but reported a net loss of $49.7 million, or $0.28 per share, widening from Q3 2023. Key achievements… [Read More]
November 08, 2024 at 11:37 am

PRISM EV Index: Navigating Uncertainty as Lucid, Rivian, and Blink Chart Their Course Amid Trump Presidency

The electric vehicle (EV) landscape in the U.S. is facing a critical moment of potential policy change and industry recalibration following the victory of President-elect Donald Trump over Vice President Kamala Harris. With a history of opposition to current EV-supportive policies, including plans to roll back vehicle emissions standards and incentives under the Environmental Protection… [Read More]
November 08, 2024 at 9:20 am

Earnings Burnout: Canopy Growth Reports Q2 Revenue Drag From Canadian Adult Use Segment

Canadian cannabis company, Canopy Growth Corporation (CGC), announced its second quarter financials and posted revenues of C$47.1M which were down 4.3% year-over-year (y/y). This loss is attributed to a (23.7%) y/y decline in its Canadian Adult-use segment. The company’s two other segments offset the Adult-use with Canadian Medical up 15.5% y/y and international markets segment… [Read More]
November 08, 2024 at 9:01 am

MNMD Q3 Snapshot: Advancing Three Phase 3 Trials with Ample Cash

MindMed (NASDAQ: MNMD) reported its third quarter 2024 financial results and provided significant business updates, highlighting its progress towards initiating multiple Phase 3 clinical trials for its lead candidate, MM120, targeting Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD). The Company is positioned for near-term catalysts, beginning with the commencement of its Phase 3… [Read More]
November 08, 2024 at 8:33 am

Stocks making the biggest moves premarket: Pinterest, Monster Beverage, Bath & Body Works, Trump Media & more

Take a look at the businesses that are making waves in the pre-market. Trump Media & Technology Group — President-elect Donald Trump’s media company’s shares took another 4.6% hit in premarket trading after dropping by 23% in the previous session. Trading under the ticker Trump’s initials, DJT, the stock has lost the gains from Wednesday’s… [Read More]
November 07, 2024 at 12:37 pm

Earnings Alert: Are Investors Swiping Left on These Two Dating App Stocks?

We’ll just come out and say it, dating sucks. In today’s world most singles have taken to dating apps which have transformed the way people connect and form relationships, to make it easier to meet new people based on shared interests, location, and preferences. Popular platforms like Tinder, Bumble, and Hinge each offer unique approaches… [Read More]
November 07, 2024 at 11:23 am

Got Oatly? Q3 Financial Results Show Revenue Growth Across All Geographic Markets

Today the oat milk producer Oatly (OTLY) has announced its Q3 financial results that illustrate year-over-year revenue growth across all of its geographic markets. Its Europe & International posted at $109.9M vs year-ago $103.5M, North America was $69.1M vs year-ago $58.5M and greater China was reported at $29.1M vs year-ago $25.6M. The overall revenue for… [Read More]
November 07, 2024 at 10:10 am

Cingulate Reports Strong Q3 with $19.5M Boost to Propel ADHD Platform, Eyes Mid-2025 NDA Submission

Cingulate Inc. (Nasdaq:CING) reported a $19.5 million increase in working capital in Q3 2024, strengthening its financial position to advance its lead ADHD asset, CTx-1301, toward a mid-2025 New Drug Application (NDA) submission. The company raised $12.5 million in capital during the quarter, extending its cash runway into Q3 2025. Additionally, Cingulate secured European patents… [Read More]
November 07, 2024 at 9:57 am

Could Tilray Medical’s Cannabis Extract Be a Breakthrough for Chemotherapy-Induced Nausea and Vomiting? Promising Report Revealed

Tilray Medical (NASDAQ: TLRY) has announced positive findings from a study examining the use of an oral cannabis extract for treating chemotherapy-induced nausea and vomiting (CINV). This condition, affecting up to 80% of cancer patients, is one of the most distressing side effects of chemotherapy, impacting patients’ quality of life, nutritional health, and overall well-being…. [Read More]